+123.2%
MPC vs GSK
+26.4%
+96.8%
-18.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 2025-09-08 to 2026-09-08.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.3% | -2.7% | +5.0% | +1.8% |
| 7D | +3.9% | -4.2% | +8.0% | +3.1% |
| 30D | +33.8% | -7.5% | +41.3% | +32.1% |
| 3M | +49.9% | -3.3% | +53.1% | +48.9% |
| 6M | +80.9% | -9.3% | +90.3% | +78.2% |
| YTD | +147.4% | +1.6% | +145.8% | +140.1% |
| 1Y | +123.2% | +25.5% | +97.7% | +118.9% |
| All | +123.2% | +26.4% | +96.8% | +118.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 2025-09-08 to 2026-09-08: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
2025-09-08 to 2026-09-08 analysis · Full analysis span regression · 6 months rolling